

Online Resource 2: Data extraction form

- Covidence ID:
- Title:
- Author(s):
- Year of publication:
- Reference (First Author's Last Name, Year):
- Name of active safety surveillance/other PV systems:
- Primary goals/aims:
- Government fund organization name (e.g., US government/EU/UK, DRC government):
- Specify funding organization name (others not government):
- Funding Source: (check all that apply)
 1. ☐ Government
 2. ☐ Foundation
 3. ☐ Educational Institute
 4. ☐ WHO
 5. ☐ NGO/Non-Profit
 6. ☐ Pharmaceutical
 7. ☐ Self-funded
 8. ☐ Other
- Current Status of Surveillance
 1. ☐ Active
 2. ☐ Inactive
 3. ☐ In preparation
 4. ☐ Not specified
 5. ☐ Other
- Start year of surveillance activities:
- End year of surveillance activities:
- Methodology: (check all that apply)

1.
 2.
 3.
 4.
 5.
 6.
- Country(ies) where surveillance is located:
 - Country representativeness: (check all that apply)
 1.
 2.
 3.
 4.
 5.
 6.
 7.
 8.
 9.
 - Medicine's specific name (e.g., Azithromycin, Artesunate):
 - Medicine's group name (e.g., Antibiotic, Antimalarial):
 - Medicine's group + specific name {e.g., Antibiotic(Azithromycin), Antimalarial (Artesunate)}:
 - Medicine's brand name {e.g., Azith(Sanofi)}:
 - Vaccine's specific name (e.g., BBIBP-CorV, BNT162b2, ChAdOx1 nCoV-19, Gam-COVID-Vac):
 - Vaccine's group name (e.g., COVID-19):
 - Vaccine's group + specific name {e.g., COVID 19: BBIBP-CorV (Sinopharm), COVID 19: BNT162b2 (Pfizer-BioNTech), COVID 19: ChAdOx1 nCoV-19 (AstraZeneca), COVID 19: Gam-COVID-Vac (Sputnik V)}:
 - Vaccine's brand name (e.g., Sinopharm, Pfizer-BioNTech, AstraZeneca, Sputnik V):
 - Participant(s)

1.
 2.
 3.
 4.
 5.
 6.
 7.
 8.
 9.
 10.
 11.
- Sample size (exact number):
 - Sample size category
 1.
 2.
 3.
 4.
 5.
 6.
 7.
 8.
 - Sources of Data Collection (check all that apply)
 1.
 2.
 3.
 4.
 5.
 6.

- 7.
- Data system used for data collection: (check all that apply)
 1.
 2.
 3.
 4.
 - Electronic data system's name (e.g., REDCap, Vigibase):
 - Purpose of mobile use (check all that apply)
 1.
 2.
 3.
 4.
 5.
 - Type of data entry (check all that apply)
 1.
 2.
 3.
 4.
 5.
 6.
 - Participant age range:
 - Gestational Age upon Recruitment (if applicable):
 - Infant/Child Outcomes (AEs):
 - Disease Focus (medicine):
 - Disease Focus (vaccine):
 - Duration of participant follow-up:
 - Characteristics of included studies:

- Strengths of the active safety surveillance/other PV system:
- Weaknesses / gaps of the active safety surveillance/other PV system:
- Does the study demonstrate flexibility to monitor new vaccines?
 1.
 2.
- If Yes, which criteria are met? (Select all that apply)
 1.
 2.
 3.
 4.
 5.
 6.
 7.
- Does the study use Brighton Collaboration tools?
 1.
 2.
- Is the study conducted in more than one country?
 1.
 2.
- If Yes, who was involved? (Select all that apply)
 1.
 2.
 3.
 4.
 5.
 6.
 7.
 8.

9.

10.